The US Patent Trial and Appeal Board has ruled against Roche in its attempts to force a patent trial of Bayer 's blood clot disorder patent . It had argued that the patent did not concern a new drug and had launched the trial after it was prevented from developing a generic version by a joint patent and J&J suit .
The US Patent Trial and Appeal Board has ruled against Mylan in its attempts to force a patent review of Bayer's blood clot disorder treatment. Mylan had argued that the patent did not concern a new invention and had launched the suit after it was prevented from selling a generic version by a joint Bayer and J&J suit.